Rare Diseases

Strategic Research Insights (SRI) has broad and deep experience across a range of rare diseases, including but not limited to Duchenne muscular dystrophy, amyotrophic lateral sclerosis (ALS), cystic fibrosis, Gaucher’s disease, metabolic disorders, genetic syndromes, and rare hematological conditions. Our expertise extends to rare neurological disorders, rare cancers, and other chronic, complex conditions that present unique challenges in diagnosis, treatment, and patient care.

SRI’s work in this area supports the development of targeted therapies by addressing the nuanced needs of small patient populations and enabling evidence-based decision-making in highly specialized markets.

SRI engages a wide variety of stakeholders, including specialist physicians, key opinion leaders, patients and caregivers, payers, health technology assessors, government agencies, pharmacy benefit managers, specialty pharmacists, hospital personnel, nurse practitioners, office managers, patient advocacy organizations, and Veterans Administration executives. SRI’s projects span qualitative and quantitative methodologies, as well as Big Data when available, delivering critical insights such as patient journey mapping, market access and reimbursement strategies, pricing, segmentation, and unmet needs assessments.

Conducted across North America, Europe, and Asia, SRI’s rare diseases research equips clients with comprehensive, multi-stakeholder intelligence necessary to navigate the complexities of rare disease commercialization and healthcare delivery effectively.